Global Cooperation and Early Access-Clinical Outcomes Matter

In this commentary on two analyses related to cancer drug approvals, the authors highlight that although using surrogate measures may reduce costs and expedite patient access to new treatments, these measures might not accurately predict overall survival benefits. Thus, rigorous post-approval testing and transparent data reporting are critical to ensure patients receive the most effective treatments.